cyanopindolol has been researched along with Cardiomyopathies, Primary in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Amour, J; Birenbaum, A; Heymes, C; Loyer, X; Michelet, P; Riou, B | 1 |
| Ikegaya, T; Kaneko, M; Kobayashi, A; Nishiyama, T; Yamazaki, N | 1 |
2 other study(ies) available for cyanopindolol and Cardiomyopathies, Primary
| Article | Year |
|---|---|
Preservation of the positive lusitropic effect of beta-adrenoceptors stimulation in diabetic cardiomyopathy.
Topics: Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Animals; Cardiomyopathies; Colforsin; Diabetes Complications; Diabetes Mellitus, Experimental; Echocardiography; In Vitro Techniques; Isoproterenol; Male; Myocardial Contraction; NG-Nitroarginine Methyl Ester; Nitric Oxide; Papillary Muscles; Phentolamine; Pindolol; Rats; Rats, Wistar; Receptors, Adrenergic, beta | 2008 |
Verapamil induced reduction of the myocardial beta-adrenoceptor density in BIO 14.6 cardiomyopathic Syrian hamsters.
Topics: Animals; Binding, Competitive; Calcium Channels; Cardiomyopathies; Cricetinae; Disease Models, Animal; Heart; Mesocricetus; Myocardium; Pindolol; Receptors, Adrenergic, beta; Verapamil | 1993 |